Gabriel Lopez-Berestein, M.D.

Peer-Reviewed Articles

1. Dragomir MP, Fuentes-Mattei E, Winkle M, Okubo K, Bayraktar R, Knutsen E, Qdaisat A, Chen M, Li Y, Shimizu M, Pang L, Liu K, Liu X, Anfossi S, Zhang H, Koch I, Tran AM, Mohapatra S, Ton A, Kaplan M, Anderson MW, Rothfuss SJ, Silasi R, Keshari RS, Ferracin M, Ivan C, Rodriguez-Aguayo C, Lopez-Berestein G, Georgescu C, Banerjee PP, Basar R, Li Z, Horst D, Vasilescu C, Bertilaccio MTS, Rezvani K, Lupu F, Yeung SC, Calin GA. Anti-miR-93-5p therapy prolongs sepsis survival by restoring the peripheral immune response. J Clin Invest 133(14), 2023. e-Pub 2023. PMID: 37261908.
2. Chakraborty D, Gutierrez-Chakraborty E, Rodriguez-Aguayo C, Basagaoglu H, Lopez-Berestein G, Amero P. Discovering genetic biomarkers for targeted cancer therapeutics with eXplainable AI. bioRxiv, 2023. e-Pub 2023. PMID: 37546729.
3. Liu Y, Ahumada AL, Bayraktar E, Schwartz P, Chowdhury M, Shi S, Sebastian MM, Khant H, de Val N, Bayram NN, Zhang G, Vu TC, Jie Z, Jennings NB, Rodriguez-Aguayo C, Swain J, Stur E, Mangala LS, Wu Y, Nagaraju S, Ermias B, Li C, Lopez-Berestein G, Braam J, Sood AK. Enhancing oral delivery of plant-derived vesicles for colitis. J Control Release 357:472-483, 2023. e-Pub 2023. PMID: 37031740.
4. Bayraktar E, Bayraktar R, Oztatlici H, Lopez-Berestein G, Amero P, Rodriguez-Aguayo C. Targeting miRNAs and Other Non-Coding RNAs as a Therapeutic Approach: An Update. Noncoding RNA 9(2), 2023. e-Pub 2023. PMID: 37104009.
5. LaFargue CJ, Amero P, Noh K, Mangala LS, Wen Y, Bayraktar E, Umamaheswaran S, Stur E, Dasari SK, Ivan C, Pradeep S, Yoo W, Lu C, Jennings NB, Vathipadiekal V, Hu W, Chelariu-Raicu A, Ku Z, Deng H, Xiong W, Choi HJ, Hu M, Kiyama T, Mao CA, Ali-Fehmi R, Birrer MJ, Liu J, Zhang N, Lopez-Berestein G, de Franciscis V, An Z, Sood AK. Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5L. Nat Commun 14(1):2407, 2023. e-Pub 2023. PMID: 37100807.
6. George J, Li Y, Kadamberi IP, Parashar D, Tsaih SW, Gupta P, Geethadevi A, Chen C, Ghosh C, Sun Y, Mittal S, Ramchandran R, Rui H, Lopez-Berestein G, Rodriguez-Aguayo C, Leone G, Rader JS, Sood AK, Dey M, Pradeep S, Chaluvally-Raghavan P. RNA-binding protein FXR1 drives cMYC translation by recruiting eIF4F complex to the translation start site. Cell Rep 42(3):112228, 2023. e-Pub 2023. PMID: 36884347.
7. Wen Y, Chelariu-Raicu A, Umamaheswaran S, Nick AM, Stur E, Hanjra P, Jiang D, Jennings NB, Chen X, Corvigno S, Glassman D, Lopez-Berestein G, Liu J, Hung MC, Sood AK. Endothelial p130cas confers resistance to anti-angiogenesis therapy. Cell Rep 42(3), 2023. PMID: 37274180.
8. Dasari SK, Joseph R, Umamaheswaran S, Mangala LS, Bayraktar E, Rodriguez-Aguayo C, Wu Y, Nguyen N, Powell RT, Sobieski M, Liu Y, Chowdhury MA, Amero P, Stephan C, Lopez-Berestein G, Westin SN, Sood AK. Combination of EphA2- and Wee1-Targeted Therapies in Endometrial Cancer. Int J Mol Sci 24(4), 2023. e-Pub 2023. PMID: 36835335.
9. Jensen DM, Han P, Mangala LS, Lopez-Berestein G, Sood AK, Liu J, Kriegel AJ, Usa K, Widlansky ME, Liang M. Broad-acting therapeutic effects of miR-29b-chitosan on hypertension and diabetic complications. Mol Ther 30(11):3462-3476, 2022. e-Pub 2022. PMID: 35965413.
10. Rodriguez-Aguayo C, Bayraktar E, Ivan C, Aslan B, Mai J, He G, Mangala LS, Jiang D, Nagaraja AS, Ozpolat B, Chavez-Reyes A, Ferrari M, Mitra R, Siddik ZH, Shen H, Yang X, Sood AK, Lopez-Berestein G. Corrigendum to "PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis" [EBioMedicine 40 (2019) 290-304]. EBioMedicine 83:104194, 2022. e-Pub 2022. PMID: 35914489.
11. Chaganty BKR, Qiu S, Lu Y, Lopez-Berestein G, Ozpolat B, Fan Z. Redirecting host preexisting influenza A virus immunity for cancer immunotherapy. Cancer Immunol Immunother 71(7):1611-1623, 2022. e-Pub 2021. PMID: 34731283.
12. Zheng Y, Sethi R, Mangala LS, Taylor C, Goldsmith J, Wang M, Masuda K, Carrami EM, Mannion D, Miranda F, Herrero-Gonzalez S, Hellner K, Chen F, Alsaadi A, Albukhari A, Fotso DC, Yau C, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Knapp S, Gray NS, Campo L, Myers KA, Dhar S, Ferguson D, Bast RC, Sood AK, von Delft F, Ahmed AA. Author Correction: Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. Nat Commun 13(1):3352, 2022. e-Pub 2022. PMID: 35688808.
13. Wen Y, Chelariu-Raicu A, Umamaheswaran S, Nick AM, Stur E, Hanjra P, Jiang D, Jennings NB, Chen X, Corvigno S, Glassman D, Lopez-Berestein G, Liu J, Hung MC, Sood AK. Endothelial p130cas confers resistance to anti-angiogenesis therapy. Cell Rep 39(12):110999, 2022. PMID: 35732127.
14. Attia YM, Salama SA, Shouman SA, Ivan C, Elsayed AM, Amero P, Rodriguez-Aguayo C, Lopez-Berestein G. Targeting CDK7 reverses tamoxifen resistance through regulating stemness in ER+ breast cancer. Pharmacol Rep 74(2):366-378, 2022. e-Pub 2022. PMID: 35000145.
15. El-Arabey AA, Denizli M, Kanlikilicer P, Bayraktar R, Ivan C, Rashed M, Kabil N, Ozpolat B, Calin GA, Salama SA, Abd-Allah AR, Sood AK, Lopez-Berestein G. CORRIGENDUM: GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma. Cell Signal 89:110147, 2022. e-Pub 2021. PMID: 34772589.
16. Wen Y, Chelariu-Raicu A, Umamaheswaran S, Nick AM, Stur E, Hanjra P, Jiang D, Jennings NB, Chen X, Corvigno S, Glassman D, Lopez-Berestein G, Liu J, Hung MC, Sood AK. Endothelial p130cas confers resistance to anti-angiogenesis therapy. Cell Rep 38(4):110301, 2022. PMID: 35081345.
17. Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, Merritt WM, Lin YG, Mangala LS, Kim TJ, Coleman RL, Landen CN, Li Y, Felix E, Sanguino AM, Newman RA, Lloyd M, Gershenson DM, Kundra V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK. Author Correction: Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 27(12):2246, 2021. PMID: 34799731.
18. George J, Li Y, Kadamberi IP, Parashar D, Tsaih SW, Gupta P, Geethadevi A, Chen C, Ghosh C, Sun Y, Mittal S, Ramchandran R, Rui H, Lopez-Berestein G, Rodriguez-Aguayo C, Leone G, Rader JS, Sood AK, Dey M, Pradeep S, Chaluvally-Raghavan P. RNA-binding protein FXR1 drives cMYC translation by recruiting eIF4F complex to the translation start site. Cell Rep 37(5):109934, 2021. PMID: 34731628.
19. Liu Y, Zhang X, Han C, Wan G, Huang X, Ivan C, Jiang D, Rodriguez-Aguayo C, Lopez-Berestein G, Rao PH, Maru DM, Pahl A, He X, Sood AK, Ellis LM, Anderl J, Lu X. Author Correction: TP53 loss creates therapeutic vulnerability in colorectal cancer. Nature 597(7875):E6, 2021. PMID: 34433970.
20. Kim HS, Han HD, Armaiz-Pena GN, Stone RL, Nam EJ, Lee JW, Shahzad MMK, Nick AM, Lee SJ, Roh JW, Nishimura M, Mangala LS, Bottsford-Miller J, Gallick GE, Lopez-Berestein G, Sood AK. Editor's Note: Functional Roles of Src and Fgr in Ovarian Carcinoma. Clin Cancer Res 27(15):4452, 2021. PMID: 34341057.
21. Han HD, Mangala LS, Lee JW, Shahzad MMK, Kim HS, Shen D, Nam EJ, Mora EM, Stone RL, Lu C, Lee SJ, Roh JW, Nick AM, Lopez-Berestein G, Sood AK. Editor's Note: Targeted Gene Silencing Using RGD-Labeled Chitosan Nanoparticles. Clin Cancer Res 27(15):4453, 2021. PMID: 34341058.
22. Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MMK, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AK. Editor's Note: Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res 27(15):4454, 2021. PMID: 34341059.
23. Ma S, Mangala LS, Hu W, Bayaktar E, Yokoi A, Hu W, Pradeep S, Lee S, Piehowski PD, Villar-Prados A, Wu SY, McGuire MH, Lara OD, Rodriguez-Aguayo C, LaFargue CJ, Jennings NB, Rodland KD, Liu T, Kundra V, Ram PT, Ramakrishnan S, Lopez-Berestein G, Coleman RL, Sood AK. CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance. Cell Rep 36(7):109549, 2021. PMID: 34407412.
24. Chakraborty D, Ivan C, Amero P, Khan M, Rodriguez-Aguayo C, Basagaoglu H, Lopez-Berestein G. Explainable Artificial Intelligence Reveals Novel Insight into Tumor Microenvironment Conditions Linked with Better Prognosis in Patients with Breast Cancer. Cancers (Basel) 13(14), 2021. e-Pub 2021. PMID: 34298668.
25. Gao C, Jin G, Forbes E, Mangala LS, Wang Y, Rodriguez-Aguayo C, Amero P, Bayraktar E, Yan Y, Lopez-Berestein G, Broaddus RR, Sood AK, Xue F, Zhang W. Inactivating Mutations of the IK Gene Weaken Ku80/Ku70-Mediated DNA Repair and Sensitize Endometrial Cancer to Chemotherapy. Cancers (Basel) 13(10), 2021. e-Pub 2021. PMID: 34065218.
26. Amero P, Lokesh GLR, Chaudhari RR, Cardenas-Zuniga R, Schubert T, Attia YM, Montalvo-Gonzalez E, Elsayed AM, Ivan C, Wang Z, Cristini V, Franciscis V, Zhang S, Volk DE, Mitra R, Rodriguez-Aguayo C, Sood AK, Lopez-Berestein G. Conversion of RNA Aptamer into Modified DNA Aptamers Provides for Prolonged Stability and Enhanced Antitumor Activity. J Am Chem Soc 143(20):7655-7670, 2021. e-Pub 2021. PMID: 33988982.
27. Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK. ATP11B mediates platinum resistance in ovarian cancer. J Clin Invest 131(7), 2021. PMID: 33792569.
28. Mangala LS, Wang H, Jiang D, Wu SY, Somasunderam A, Volk DE, Lokesh GLR, Li X, Pradeep S, Yang X, Haemmerle M, Rodriguez-Aguayo C, Nagaraja AS, Rupaimoole R, Bayraktar E, Bayraktar R, Li L, Tanaka T, Hu W, Ivan C, Gharpure KM, McGuire MH, Thiviyanathan V, Zhang X, Maiti SN, Bulayeva N, Choi HJ, Dorniak PL, Cooper LJ, Rosenblatt KP, Lopez-Berestein G, Gorenstein DG, Sood AK. Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy. JCI Insight 6(7), 2021. e-Pub 2021. PMID: 33793423.
29. Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK. Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight 6(7), 2021. e-Pub 2021. PMID: 33793425.
30. Siedel JH, Ring KL, Hu W, Dood RL, Wang Y, Baggerly K, Darcy KM, Conrads TP, Gallagher S, Tshiaba P, Neff C, Timms KM, Mangala S, Westin SN, Broaddus R, Lopez-Berestein G, Lu KH, Coleman RL, Maxwell GL, Sood AK. Clinical significance of homologous recombination deficiency score testing in endometrial Cancer. Gynecol Oncol 160(3):777-785, 2021. e-Pub 2021. PMID: 33563487.
31. Gorur A, Bayraktar R, Ivan C, Mokhlis HA, Bayraktar E, Kahraman N, Karakas D, Karamil S, Kabil NN, Kanlikilicer P, Aslan B, Tamer L, Wang Z, Cristini V, Lopez-Berestein G, Calin G, Ozpolat B. ncRNA therapy with miRNA-22-3p suppresses the growth of triple-negative breast cancer. Mol Ther Nucleic Acids 23:930-943, 2021. e-Pub 2021. PMID: 33614241.
32. Ma S, McGuire MH, Mangala LS, Lee S, Stur E, Hu W, Bayraktar E, Villar-Prados A, Ivan C, Wu SY, Yokoi A, Dasari SK, Jennings NB, Liu J, Lopez-Berestein G, Ram P, Sood AK. Gain-of-function p53 protein transferred via small extracellular vesicles promotes conversion of fibroblasts to a cancer-associated phenotype. Cell Rep 34(6):108726, 2021. PMID: 33567287.
33. Elsayed AM, Bayraktar E, Amero P, Salama SA, Abdelaziz AH, Ismail RS, Zhang X, Ivan C, Sood AK, Lopez-Berestein G, Rodriguez-Aguayo C. PRKAR1B-AS2 Long Noncoding RNA Promotes Tumorigenesis, Survival, and Chemoresistance via the PI3K/AKT/mTOR Pathway. Int J Mol Sci 22(4), 2021. e-Pub 2021. PMID: 33668685.
34. Noh K, Bach DH, Choi HJ, Kim MS, Wu SY, Pradeep S, Ivan C, Cho MS, Bayraktar E, Rodriguez-Aguayo C, Dasari SK, Stur E, Mangala LS, Lopez-Berestein G, Sood AK. The hidden role of paxillin: localization to nucleus promotes tumor angiogenesis. Oncogene 40(2):384-395, 2021. e-Pub 2020. PMID: 33149280.
35. Mangala LS, Rodriguez-Aguayo C, Bayraktar E, Jennings NB, Lopez-Berestein G, Sood AK. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models. Methods Mol Biol 2372:157-168, 2021. PMID: 34417750.
36. Amero P, Khatua S, Rodriguez-Aguayo C, Lopez-Berestein G. Aptamers: Novel Therapeutics and Potential Role in Neuro-Oncology. Cancers (Basel) 12(10), 2020. e-Pub 2020. PMID: 33050158.
37. Yang H, Mao W, Rodriguez-Aguayo C, Mangala LS, Bartholomeusz G, Iles LR, Jennings NB, Ahmed AA, Sood AK, Lopez-Berestein G, Lu Z, Bast RC. Correction: Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability. Clin Cancer Res 26(18):5050, 2020. PMID: 32934031.
38. Miyake TM, Pradeep S, Bayraktar E, Stur E, Handley KF, Wu SY, Rodriguez-Aguayo C, Lee JS, Lopez-Berestein G, Coleman RL, Sood AK. NRG1/ERBB3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors. Mol Cancer Ther 19(8):1727-1735, 2020. e-Pub 2020. PMID: 32499298.
39. Elsayed AM, Amero P, Salama SA, Abdelaziz AH, Lopez-Berestein G, Rodriguez-Aguayo C. Back to the Future: Rethinking the Great Potential of lncRNAS for Optimizing Chemotherapeutic Response in Ovarian Cancer. Cancers (Basel) 12(9), 2020. e-Pub 2020. PMID: 32854207.
40. Lara OD, Bayraktar E, Amero P, Ma S, Ivan C, Hu W, Wang Y, Mangala LS, Dutta P, Bhattacharya P, Ashizawa AT, Lopez-Berestein G, Rodriguez-Aguayo C, Sood AK. Therapeutic efficacy of liposomal Grb2 antisense oligodeoxynucleotide (L-Grb2) in preclinical models of ovarian and uterine cancer. Oncotarget 11(29):2819-2833, 2020. e-Pub 2020. PMID: 32754300.
41. Gray MJ, Dallas NA, Van Buren G, Xia L, Yang AD, Somcio RJ, Gaur P, Mangala LS, Vivas-Mejia PE, Fan F, Sanguino AM, Gallick GE, Lopez-Berestein G, Sood AK, Ellis LM. Correction: Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver. Oncogene 39(23):4619, 2020. PMID: 32366906.
42. Krzeszinski JY, Wei W, Huynh H, Jin Z, Wang X, Chang TC, Xie XJ, He L, Mangala LS, Lopez-Berestein G, Sood AK, Mendell JT, Wan Y. Retraction Note: miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2. Nature 582(7810):134, 2020. PMID: 32483375.
43. Rupaimoole R, Wu SY, Pradeep S, Ivan C, Pecot CV, Gharpure KM, Nagaraja AS, Armaiz-Pena GN, McGuire M, Zand B, Dalton HJ, Filant J, Miller JB, Lu C, Sadaoui NC, Mangala LS, Taylor M, van den Beucken T, Koch E, Rodriguez-Aguayo C, Huang L, Bar-Eli M, Wouters BG, Radovich M, Ivan M, Calin GA, Zhang W, Lopez-Berestein G, Sood AK. Author Correction: Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nat Commun 11(1):2867, 2020. e-Pub 2020. PMID: 32493919.
44. El-Arabey AA, Denizli M, Kanlikilicer P, Bayraktar R, Ivan C, Rashed M, Kabil N, Ozpolat B, Calin GA, Salama SA, Abd-Allah AR, Sood AK, Lopez-Berestein G. GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma. Cell Signal 68:109539, 2020. e-Pub 2020. PMID: 31935430.
45. Attia YM, Shouman SA, Salama SA, Ivan C, Elsayed AM, Amero P, Rodriguez-Aguayo C, Lopez-Berestein G. Blockade of CDK7 Reverses Endocrine Therapy Resistance in Breast Cancer. Int J Mol Sci 21(8), 2020. e-Pub 2020. PMID: 32340192.
46. Kanlikilicer P, Bayraktar R, Denizli M, Rashed MH, Ivan C, Aslan B, Mitra R, Karagoz K, Bayraktar E, Zhang X, Rodriguez-Aguayo C, El-Arabey AA, Kahraman N, Baydogan S, Ozkayar O, Gatza ML, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein G. Corrigendum to 'Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer' [EBioMedicine 38 (2018) 100-112]. EBioMedicine 52:102630, 2020. e-Pub 2020. PMID: 31972470.
47. Pichler M, Rodriguez-Aguayo C, Nam SY, Dragomir MP, Bayraktar R, Anfossi S, Knutsen E, Ivan C, Fuentes-Mattei E, Lee SK, Ling H, Catela Ivkovic T, Huang G, Huang L, Okugawa Y, Katayama H, Taguchi A, Bayraktar E, Bhattacharya R, Amero P, He WR, Tran AM, Vychytilova-Faltejskova P, Klec C, Bonilla DL, Zhang X, Kapitanovic S, Loncar B, Gafà R, Wang Z, Cristini V, Hanash SM, Bar-Eli M, Lanza G, Slaby O, Goel A, Rigoutsos I, Lopez-Berestein G, Calin GA. Therapeutic potential of FLANC, a novel primate-specific long non-coding RNA in colorectal cancer. Gut. e-Pub 2020. PMID: 31988194.
48. Xu X, Wang Y, Mojumdar K, Zhou Z, Jeong KJ, Mangala LS, Yu S, Tsang YH, Rodriguez-Aguayo C, Lu Y, Lopez-Berestein G, Sood AK, Mills GB, Liang H. A-to-I-edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis. J Clin Invest 129(12):5343-5356, 2019. PMID: 31682236.
49. Oncul S, Amero P, Rodriguez-Aguayo C, Calin GA, Sood AK, Lopez-Berestein G. Long non-coding RNAs in ovarian cancer: expression profile and functional spectrum. RNA Biol:1-12. e-Pub 2019. PMID: 31847695.
50. Parashar D, Geethadevi A, Aure MR, Mishra J, George J, Chen C, Mishra MK, Tahiri A, Zhao W, Nair B, Lu Y, Mangala LS, Rodriguez-Aguayo C, Lopez-Berestein G, Camara AKS, Liang M, Rader JS, Ramchandran R, You M, Sood AK, Kristensen VN, Mills GB, Pradeep S, Chaluvally-Raghavan P. miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer. Cell Rep 29(13):4389-4406.e10, 2019. PMID: 31875548.
51. Yang H, Shu Z, Jiang Y, Mao W, Pang L, Redwood A, Jeter-Jones SL, Jennings NB, Ornelas A, Zhou J, Rodriguez-Aguayo C, Bartholomeusz G, Iles LR, Zacharias NM, Millward SW, Lopez-Berestein G, Le XF, Ahmed AA, Piwnica-Worms H, Sood AK, Bast RC, Lu Z. 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers. Clin Cancer Res 25(18):5702-5716, 2019. e-Pub 2019. PMID: 31391192.
52. Chen X, Mangala LS, Mooberry L, Bayraktar E, Dasari SK, Ma S, Ivan C, Court KA, Rodriguez-Aguayo C, Bayraktar R, Raut S, Sabnis N, Kong X, Yang X, Lopez-Berestein G, Lacko AG, Sood AK. Identifying and targeting angiogenesis-related microRNAs in ovarian cancer. Oncogene 38(33):6095-6108, 2019. e-Pub 2019. PMID: 31289363.
53. Gunaratne PH, Pan Y, Rao AK, Lin C, Hernandez-Herrera A, Liang K, Rait AS, Venkatanarayan A, Benham AL, Rubab F, Kim SS, Rajapakshe K, Chan CK, Mangala LS, Lopez-Berestein G, Sood AK, Rowat AC, Coarfa C, Pirollo KF, Flores ER, Chang EH. Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53-altered tumors. Cancer 125(14):2409-2422, 2019. e-Pub 2019. PMID: 31012964.
54. Park YY, Jung SY, Jennings NB, Rodriguez-Aguayo C, Peng G, Lee SR, Kim SB, Kim K, Leem SH, Lin SY, Lopez-Berestein G, Sood AK, Lee JS. Corrigendum: FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis 40(7):936, 2019. PMID: 31063534.
55. Amano H, Chaudhury A, Rodriguez-Aguayo C, Lu L, Akhanov V, Catic A, Popov YV, Verdin E, Johnson H, Stossi F, Sinclair DA, Nakamaru-Ogiso E, Lopez-Berestein G, Chang JT, Neilson JR, Meeker A, Finegold M, Baur JA, Sahin E. Telomere Dysfunction Induces Sirtuin Repression that Drives Telomere-Dependent Disease. Cell Metab 29(6):1274-1290.e9, 2019. e-Pub 2019. PMID: 30930169.
56. Azam SH, Porrello A, Harrison EB, Leslie PL, Liu X, Waugh TA, Belanger A, Mangala LS, Lopez-Berestein G, Wilson HL, McCann JV, Kim WY, Sood AK, Liu J, Dudley AC, Pecot CV. Quaking orchestrates a post-transcriptional regulatory network of endothelial cell cycle progression critical to angiogenesis and metastasis. Oncogene 38(26):5191-5210, 2019. e-Pub 2019. PMID: 30918328.
57. Krzeszinski JY, Wei W, Huynh H, Jin Z, Wang X, Chang TC, Xie XJ, He L, Mangala LS, Lopez-Berestein G, Sood AK, Mendell JT, Wan Y. Author Correction: miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2. Nature 570(7761):E51, 2019. PMID: 31127195.
58. McGuire MH, Herbrich SM, Dasari SK, Wu SY, Wang Y, Rupaimoole R, Lopez-Berestein G, Baggerly KA, Sood AK. Pan-cancer genomic analysis links 3'UTR DNA methylation with increased gene expression in T cells. EBioMedicine 43:127-137, 2019. e-Pub 2019. PMID: 31056473.
59. Halder J, Kamat AA, Landen CN, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AK. Correction: Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy. Clin Cancer Res 25(10):3194, 2019. PMID: 31092618.
60. Mokhlis HA, Bayraktar R, Kabil NN, Caner A, Kahraman N, Rodriguez-Aguayo C, Zambalde EP, Sheng J, Karagoz K, Kanlikilicer P, Abdel Aziz AAH, Abdelghany TM, Ashour AA, Wong S, Gatza ML, Calin GA, Lopez-Berestein G, Ozpolat B. The Modulatory Role of MicroRNA-873 in the Progression of KRAS-Driven Cancers. Mol Ther Nucleic Acids 14:301-317, 2019. e-Pub 2018. PMID: 30654191.
61. Villar-Prados A, Wu SY, Court KA, Ma S, LaFargue C, Chowdhury MA, Engelhardt MI, Ivan C, Ram PT, Wang Y, Baggerly K, Rodriguez-Aguayo C, Lopez-Berestein G, Ming-Yang S, Maloney DJ, Yoshioka M, Strovel JW, Roszik J, Sood AK. Predicting novel therapies and targets: Regulation of Notch3 by the bromodomain protein BRD4. Mol Cancer Ther 18(2):421-436, 2019. e-Pub 2018. PMID: 30420565.
62. Rodriguez-Aguayo C, Bayraktar E, Ivan C, Aslan B, Mai J, He G, Mangala LS, Jiang D, Nagaraja AS, Ozpolat B, Chavez-Reyes A, Ferrari M, Mitra R, Siddik ZH, Shen H, Yang X, Sood AK, Lopez-Berestein G. PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis. EBioMedicine 40:290-304, 2019. e-Pub 2019. PMID: 30655206.
63. Hisamatsu T, McGuire M, Wu SY, Rupaimoole R, Pradeep S, Bayraktar E, Noh K, Hu W, Hansen JM, Lyons Y, Gharpure KM, Nagaraja AS, Mangala LS, Mitamura T, Rodriguez-Aguayo C, Eun YG, Rose J, Bartholomeusz G, Ivan C, Lee JS, Matsuo K, Frumovitz M, Wong KK, Lopez-Berestein G, Sood AK. PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer. Mol Cancer Ther 18(1):162-172, 2019. e-Pub 2018. PMID: 30305341.
64. Gonzalez-Villasana V, Rashed MH, Gonzalez-Cantú Y, Bayraktar R, Menchaca-Arredondo JL, Vazquez-Guillen JM, Rodriguez-Padilla C, Lopez-Berestein G, Resendez-Perez D. Presence of Circulating miR-145, miR-155, and miR-382 in Exosomes Isolated from Serum of Breast Cancer Patients and Healthy Donors. Dis Markers 2019:6852917, 2019. e-Pub 2019. PMID: 30891102.
65. Tekedereli I, Akar U, Alpay SN, Lopez-Berestein G, Ozpolat B. Autophagy is Required to Regulate Mitochondria Renewal, Cell Attachment, and All-trans-Retinoic Acid-Induced Differentiation in NB4 Acute Promyelocytic Leukemia Cells. J Environ Pathol Toxicol Oncol 38(1):13-20, 2019. PMID: 30806286.
66. Kanlikilicer P, Bayraktar R, Denizli M, Rashed MH, Ivan C, Aslan B, Mitra R, Karagoz K, Bayraktar E, Zhang X, Rodriguez-Aguayo C, El-Arabey AA, Kahraman N, Baydogan S, Ozkayar O, Gatza ML, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein G. Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer. EBioMedicine 38:100-112, 2018. e-Pub 2018. PMID: 30487062.
67. González-González A, Muñoz-Muela E, Marchal JA, Cara FE, Molina MP, Cruz-Lozano M, Jiménez G, Verma A, Ramírez A, Qian W, Chen W, Kozielski AJ, Elemento O, Martín-Salvago MD, Luque RJ, Rosa-Garrido C, Landeira D, Quintana-Romero M, Rosato RR, García MA, Ramirez-Tortosa CL, Kim H, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Lorente JA, Sánchez-Rovira P, Chang JC, Granados-Principal S. Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling. Clin Cancer Res 24(22):5697-5709, 2018. e-Pub 2018. PMID: 30012564.
68. Kabil N, Bayraktar R, Kahraman N, Mokhlis HA, Calin GA, Lopez-Berestein G, Ozpolat B. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer. Breast Cancer Res Treat 171(3):593-605, 2018. e-Pub 2018. PMID: 29971628.
69. Yang H, Mao W, Rodriguez-Aguayo C, Mangala LS, Bartholomeusz G, Iles LR, Jennings NB, Ahmed AA, Sood AK, Lopez-Berestein G, Lu Z, Bast RC. Paclitaxel Sensitivity of Ovarian Cancer can be enhanced by knocking down Pairs of Kinases that regulate MAP4 Phosphorylation and Microtubule Stability. Clin Cancer Res 24(20):5072-5084, 2018. e-Pub 2018. PMID: 30084832.
70. Inoue K, Deng Z, Chen Y, Giannopoulou E, Xu R, Gong S, Greenblatt MB, Mangala LS, Lopez-Berestein G, Kirsch DG, Sood AK, Zhao L, Zhao B. Bone protection by inhibition of microRNA-182. Nat Commun 9(1):4108, 2018. e-Pub 2018. PMID: 30291236.
71. Bayraktar R, Ivan C, Bayraktar E, Kanlikilicer P, Kabil NN, Kahraman N, Mokhlis HA, Karakas D, Rodriguez-Aguayo C, Arslan A, Sheng J, Wong S, Lopez-Berestein G, Calin GA, Ozpolat B. Dual suppressive effect of microRNA-34a on the FOXM1/eEF2-kinase axis regulates triple-negative breast cancer growth and invasion. Clin Cancer Res 24(17):4225-4241, 2018. e-Pub 2018. PMID: 29748184.
72. Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK. ATP11B mediates platinum resistance in ovarian cancer. J Clin Invest 128(7):3199, 2018. e-Pub 2018. PMID: 29809169.
73. Gharpure KM, Pradeep S, Sans M, Rupaimoole R, Ivan C, Wu SY, Bayraktar E, Nagaraja AS, Mangala LS, Zhang X, Haemmerle M, Hu W, Rodriguez-Aguayo C, McGuire M, Mak CSL, Chen X, Tran MA, Villar-Prados A, Pena GA, Kondetimmanahalli R, Nini R, Koppula P, Ram P, Liu J, Lopez-Berestein G, Baggerly K, S Eberlin L, Sood AK. FABP4 as a key determinant of metastatic potential of ovarian cancer. Nat Commun 9(1):2923, 2018. e-Pub 2018. PMID: 30050129.
74. Allen JK, Armaiz-Pena GN, Nagaraja AS, Sadaoui NC, Ortiz T, Dood R, Ozcan M, Herder DM, Haemmerle M, Gharpure KM, Rupaimoole R, Previs RA, Wu SY, Pradeep S, Xu X, Han HD, Zand B, Dalton HJ, Taylor M, Hu W, Bottsford-Miller J, Moreno-Smith M, Kang Y, Mangala LS, Rodriguez-Aguayo C, Sehgal V, Spaeth EL, Ram PT, Wong STC, Marini FC, Lopez-Berestein G, Cole SW, Lutgendorf SK, De Biasi M, Sood AK. Sustained adrenergic signaling promotes intratumoral innervation through BDNF induction. Cancer Res 78(12):3233-3242, 2018. e-Pub 2018. PMID: 29661830.
75. Mangala LS, Wang H, Jiang D, Wu SY, Somasunderam A, Volk DE, Lokesh GLR, Li X, Pradeep S, Yang X, Haemmerle M, Rodriguez-Aguayo C, Nagaraja AS, Rupaimoole R, Bayraktar E, Bayraktar R, Li L, Tanaka T, Hu W, Ivan C, Gharpure KM, McGuire MH, Thiviyanathan V, Zhang X, Maiti SN, Bulayeva N, Choi HJ, Dorniak PL, Cooper LJ, Rosenblatt KP, Lopez-Berestein G, Gorenstein DG, Sood AK. Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy. JCI Insight 3(3):11, 2018. e-Pub 2018. PMID: 29889661.
76. Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK. Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight 3(11), 2018. e-Pub 2018. PMID: 29889660.
77. Shahzad MMK, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, Nishimura M, Lee JW, Jennings NB, Bottsford-Miller J, Vivas-Mejia P, Lutgendorf SK, Lopez-Berestein G, Bar-Eli M, Cole SW, Sood AK. Stress effects on FosB and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem 293(26):10041, 2018. PMID: 29959278.
78. Zhang P, Xiao Z, Wang S, Zhang M, Wei Y, Hang Q, Kim J, Yao F, Rodriguez-Aguayo C, Ton BN, Lee M, Wang Y, Zhou Z, Zeng L, Hu X, Lawhon SE, Siverly AN, Su X, Li J, Xie X, Cheng X, Liu LC, Chang HW, Chiang SF, Lopez-Berestein G, Sood AK, Chen J, You MJ, Sun SC, Liang H, Huang Y, Yang X, Sun D, Sun Y, Hung MC, Ma L. ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer. Cell Rep 23(3):823-837, 2018. PMID: 29669287.
79. Chen X, Mangala LS, Rodriguez-Aguayo C, Kong X, Lopez-Berestein G, Sood AK. RNA interference-based therapy and its delivery systems. Cancer Metastasis Rev 37(1):107-124, 2018. PMID: 29243000.
80. Zheng Y, Sethi R, Mangala LS, Taylor C, Goldsmith J, Wang M, Masuda K, Karaminejadranjbar M, Mannion D, Miranda F, Herrero-Gonzalez S, Hellner K, Chen F, Alsaadi A, Albukhari A, Fotso DC, Yau C, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Knapp S, Gray NS, Campo L, Myers KA, Dhar S, Ferguson D, Bast RC, Sood AK, von Delft F, Ahmed AA. Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. Nat Commun 9(1):476, 2018. e-Pub 2018. PMID: 29396402.
81. Leung CS, Yeung TL, Yip KP, Wong KK, Ho SY, Mangala LS, Sood AK, Lopez-Berestein G, Sheng J, Wong ST, Birrer MJ, Mok SC. Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance. J Clin Invest 128(2):589-606, 2018. e-Pub 2017. PMID: 29251630.
82. Mitamura T, Pradeep S, McGuire M, Wu SY, Ma S, Hatakeyama H, Lyons YA, Hisamatsu T, Noh K, Villar-Prados A, Chen X, Ivan C, Rodriguez-Aguayo C, Hu W, Lopez-Berestein G, Coleman RL, Sood AK. Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP). Oncogene 37(6):722-731, 2018. e-Pub 2017. PMID: 29059175.
83. Lu Y, Hu Z, Mangala LS, Stine ZE, Hu X, Jiang D, Xiang Y, Zhang Y, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, DeMarzo AM, Sood AK, Zhang L, Dang CV. MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels. Cancer Res 78(1):64-74, 2018. e-Pub 2017. PMID: 29180471.
84. Liu Y, Choi DS, Sheng J, Ensor JE, Liang DH, Rodriguez-Aguayo C, Polley A, Benz S, Elemento O, Verma A, Cong Y, Wong H, Qian W, Li Z, Granados-Principal S, Lopez-Berestein G, Landis MD, Rosato RR, Dave B, Wong S, Marchetti D, Sood AK, Chang JC. HN1L Promotes Triple-Negative Breast Cancer Stem Cells through LEPR-STAT3 Pathway. Stem Cell Reports 10(1):212-227, 2018. e-Pub 2017. PMID: 29249663.

Book Chapters

1. Rodriguez-Aguayo C, Chavez-Reyes A, Lopez-Berestein G, Sood AK. Advanced Delivery and Therapeutic Applications of RNAi. In: RNAi in Cancer Therapy. John Wiley & Sons. Inc.
2. Tekedereli I, Lopez-Berestein G, Ozpolat B. Induction of Autophagic Cell Death by Targeting Bcl-2 as A Novel Theraputic Strategy in Breast Cancer. In: Breast Cancer. Open Access.
3. Ozpolat B, Akar U, Dalby K, Lopez-Berestein G. Induction of Autophagic Cell Death by Polyphenolic Compounds in Cancer: A Novel Strategy to Treat Cancer. In: Cell Death Mechanisms in Cancer. Springer.